Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06328465 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases

Study acronym: fREEDOM
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
The aim of this study is to understand whether DWB-MRI (Diffusion Whole Body-Magnetic Resonance Imaging) is useful for early detection of locoregional or distant recurrence and whether early diagnosis influences the prognosis in high-risk populations thanks to the possibility of being able to use a more effective treatment. The primary objective is to evaluate 5-year overall survival (OS) in patients with Human Epidermal Growth Factor Receptor 2 positive (HER2+) or high-risk Triple Negative (TN) undergoing surveillance with DWB-MRI.
Trial Details
NCT Number NCT06328465
Lead Sponsor European Institute of Oncology
Conditions
(from sponsor)		 Invasive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
Related terms Triple Negative Breast Neoplasms
Enrollment 145 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov